BioAtla Inc (NASDAQ:BCAB) does about 457.33K shares in volume on a normal day but saw 1201480 shares change hands in Monday’s trading. The company now has a market cap of 162.04M USD. Its current market price is $3.39, marking a decrease of -1.45% compared to the previous close of $3.44. The 52 week high reached by this stock is $4.07 whilst the lowest price level in 52 weeks is $1.24.
BioAtla Inc (BCAB) has a 20-day trading average at $2.72 and the current price is -16.67% off the 52-week high compared with 173.39% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.52 and its 200-day simple moving average is $2.33. If we look at the stock’s price movements over the week, volatility stands at 14.74%, which decreases to 9.54% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 67.97 to suggest the stock is neutral.
The consensus objective for the share price is $11.50, suggesting that the stock has a potential upside of 70.52% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on September 15, 2022 when JMP Securities initiated the stock to “Mkt Outperform” and issued a price target of $17. Credit Suisse downgraded the stock to “Neutral” from Outperform on May 05, 2022 at a price target of $35-$5. H.C. Wainwright initiated its price target at $25.
BioAtla Inc (BCAB) stock is up 40.66% over the week and 25.56% over the past month. Its price is 37.80% year-to-date and 35.06% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2023, with the company’s earnings per share (EPS) of -$0.7 above consensus estimates by $0.1. BCAB’s earnings per share are forecast to shrink by -0.70% this year and 30.10% over next year.
To reach the target analysts have set, the stock logically needs to grow 70.52 percent from here.
Outstanding shares total 48.08M with insiders holding 9.69% of the shares and institutional holders owning 64.79% of the company’s common stock. The company has a return on investment of -172.65% and return on equity of -98.37%. The beta has a value of 1.06. Price to book ratio is 2.31.
